The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Cardiff Oncology Inc (NASDAQ: CRDF) closed at $4.28 in the last session, down -3.82% from day before closing price of $4.45. In other words, the price has decreased by -$3.82 from its previous closing price. On the day, 1.59 million shares were traded. CRDF stock price reached its highest trading level at $4.555 during the session, while it also had its lowest trading level at $4.27.
Ratios:
We take a closer look at CRDF’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.22 and its Current Ratio is at 6.22. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ladenburg Thalmann on July 08, 2025, initiated with a Buy rating and assigned the stock a target price of $19.
On June 24, 2025, Jefferies started tracking the stock assigning a Hold rating and target price of $3.50.
On September 06, 2024, Craig Hallum started tracking the stock assigning a Buy rating and target price of $8.Craig Hallum initiated its Buy rating on September 06, 2024, with a $8 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 17 ’24 when Levine James E. bought 2,752 shares for $5.42 per share. The transaction valued at 14,905 led to the insider holds 65,316 shares of the business.
Levine James E. bought 2,400 shares of CRDF for $12,000 on Dec 18 ’24. The Chief Financial Officer now owns 67,716 shares after completing the transaction at $5.00 per share. On Dec 16 ’24, another insider, Levine James E., who serves as the Chief Financial Officer of the company, bought 2,564 shares for $3.83 each. As a result, the insider paid 9,820 and bolstered with 62,564 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRDF now has a Market Capitalization of 284730880 and an Enterprise Value of 131025440. For the stock, the TTM Price-to-Sale (P/S) ratio is 482.59 while its Price-to-Book (P/B) ratio in mrq is 4.02. Its current Enterprise Value per Revenue stands at 223.212 whereas that against EBITDA is -2.534.
Stock Price History:
The Beta on a monthly basis for CRDF is 1.57, which has changed by 0.82127655 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, CRDF has reached a high of $5.64, while it has fallen to a 52-week low of $2.01. The 50-Day Moving Average of the stock is 24.73%, while the 200-Day Moving Average is calculated to be 25.68%.
Shares Statistics:
According to the various share statistics, CRDF traded on average about 1.13M shares per day over the past 3-months and 1255980 shares per day over the past 10 days. A total of 66.53M shares are outstanding, with a floating share count of 60.75M. Insiders hold about 8.68% of the company’s shares, while institutions hold 42.08% stake in the company. Shares short for CRDF as of 1749772800 were 17289872 with a Short Ratio of 16.27, compared to 1747267200 on 17522454. Therefore, it implies a Short% of Shares Outstanding of 17289872 and a Short% of Float of 26.680002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are eagerly awaiting the insights provided by 5.0 analysts currently analyzing and rating the stock of Cardiff Oncology Inc (CRDF).The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.17 and low estimates of -$0.25.
Analysts are recommending an EPS of between -$0.63 and -$0.98 for the fiscal current year, implying an average EPS of -$0.84. EPS for the following year is -$0.95, with 5.0 analysts recommending between -$0.63 and -$1.14.
Revenue Estimates
A total of 7 analysts have provided revenue estimates for CRDF’s current fiscal year. The highest revenue estimate was $559k, while the lowest revenue estimate was $100k, resulting in an average revenue estimate of $383.71k. In the same quarter a year ago, actual revenue was $683k
